Top

Published in:

01-11-2020 | Cystectomy | Original Article

Survival of contemporary patients with non-metastatic urachal vs. non-urachal adenocarcinoma of the urinary bladder

Authors: Stefano Luzzago, Carlotta Palumbo, Giuseppe Rosiello, Angela Pecoraro, Marina Deuker, Francesco Alessandro Mistretta, Zhe Tian, Gennaro Musi, Emanuele Montanari, Shahrokh F. Shariat, Fred Saad, Alberto Briganti, Ottavio de Cobelli, Pierre I. Karakiewicz

Published in: World Journal of Urology | Issue 11/2020

Abstract

Purpose

To test the effect of tumor location (urachal vs. non-urachal) on cancer-specific mortality (CSM) in patients with adenocarcinoma of the urinary bladder (ADKUB).

Materials and methods

Within the Surveillance, Epidemiology, and End Results registry (2004–2016), we identified patients with non-metastatic (≤ T4N0M0) ADKUB. Stratification was made according to tumor location: urachal vs. non-urachal ADKUB. Kaplan–Meier plots and multivariable Cox regression models were fitted before and after 1:3 propensity score (PS) matching and separate Cox regression models were refitted before and after inverse probability of treatment weighting (IPTW).

Results

Of 1681 patients, 226 (13.5%) vs. 1455 (86.5%) harboured urachal vs. non-urachal ADKUB, respectively. Five-year cancer-specific survival (CSS) rates were, respectively, 75 vs. 67% for urachal vs. non-urachal ADKUB (p = 0.001). In subgroup analyses of ≤ T2N0M0 patients, 5-year CSS rates were, respectively, 84 vs. 73% for urachal vs. non-urachal ADKUB (p = 0.006). In subgroup analyses of T3-4N0M0 patients, 5-year CSS rates were, respectively, 68 vs. 49% for urachal vs. non-urachal ADKUB (p < 0.001). In multivariable Cox regression models, urachal ADKUB was associated with lower CSM rates (HR 0.6; p = 0.01). Virtually, the same findings were recorded after 1:3 PS matching (HR 0.6; p = 0.009) as well as when Cox regression models were refitted after IPTW (HR 0.7; p = 0.01).

Conclusion

The distinction between urachal vs. non-urachal ADKUB indicates better prognosis when the origin of the tumor is urachal, regardless of methodological approach used for the comparison.

Available only for authorised users

Moschini M, D’Andrea D, Korn S et al (2017) Characteristics and clinical significance of histological variants of bladder cancer. Nat Rev Urol 14:651CrossRefPubMed

Baumeister P, Zamboni S, Mattei A et al (2019) Histological variants in non-muscle invasive bladder cancer. Transl Androl Urol 8:34–38. https://doi.org/10.21037/tau.2019.01.09CrossRefPubMedPubMedCentral

Manunta A, Vincendeau S, Kiriakou G et al (2005) Non-transitional cell bladder carcinomas. BJU Int 95:497–502. https://doi.org/10.1111/j.1464-410X.2005.05327.xCrossRefPubMed

Szarvas T, Módos O, Niedworok C et al (2016) Clinical, prognostic, and therapeutic aspects of urachal carcinoma—a comprehensive review with meta-analysis of 1010 cases. Urol Oncol Semin Orig Investig 34:388–398. https://doi.org/10.1016/j.urolonc.2016.04.012CrossRef

Siefker-Radtke A (2006) Urachal carcinoma: surgical and chemotherapeutic options. Expert Rev Anticancer Ther 6:1715–1721. https://doi.org/10.1586/14737140.6.12.1715CrossRefPubMed

Flaig TW, Spiess PE, Agarwal N et al (2018) NCCN guidelines insights: bladder cancer, version 52018. J Natl Compr Cancer Netw. https://doi.org/10.6004/jnccn.2018.0072CrossRef

Wright JL, Porter MP, Li CI et al (2006) Differences in survival among patients with urachal and nonurachal adenocarcinomas of the bladder. Cancer 107:721–728. https://doi.org/10.1002/cncr.22059CrossRefPubMed

Dutta R, Abdelhalim A, Martin JW et al (2016) Effect of tumor location on survival in urinary bladder adenocarcinoma: a population-based analysis. Urol Oncol Semin Orig Investig 34:531.e1–531.e6. https://doi.org/10.1016/j.urolonc.2016.06.009CrossRef

Dandekar NP, Dalal AV, Tongaonkar HB, Kamat MR (1997) Adenocarcinoma of bladder. Eur J Surg Oncol 23:157–160. https://doi.org/10.1016/S0748-7983(97)80012-1CrossRefPubMed

10.

Cho SY, Moon KC, Park JH et al (2013) Outcomes of Korean patients with clinically localized urachal or non-urachal adenocarcinoma of the bladder. Urol Oncol Semin Orig Investig 31:24–31. https://doi.org/10.1016/j.urolonc.2010.10.002CrossRef

11.

Grignon DJ, Ro JY, Ayala AG et al (1991) Primary adenocarcinoma of the urinary bladder. A clinicopathologic analysis of 72 cases. Cancer. https://doi.org/10.1002/1097-0142(19910415)67:8%3c2165:AID-CNCR2820670827%3e3.0.CO;2-MCrossRefPubMed

12.

Austin PC (2011) An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res. https://doi.org/10.1080/00273171.2011.568786CrossRef

13.

Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF et al (2015) SEER cancer statistics review, 1975–2012. National Cancer Institute, Bethesda, MD

14.

Edge SB, Compton CC (2010) The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17:1471–1474CrossRefPubMed

15.

Dhillon J, Liang Y, Kamat AM et al (2015) Urachal carcinoma: a pathologic and clinical study of 46 cases. Hum Pathol 46:1808–1814. https://doi.org/10.1016/j.humpath.2015.07.021CrossRefPubMedPubMedCentral

16.

Molina JR, Quevedo JF, Furth AF et al (2007) Predictors of survival from urachal cancer: a mayo clinic study of 49 cases. Cancer 110:2434–2440. https://doi.org/10.1002/cncr.23070CrossRefPubMed

17.

Collazo-Lorduy A, Castillo-Martin M, Wang L et al (2016) Urachal carcinoma shares genomic alterations with colorectal carcinoma and may respond to epidermal growth factor inhibition. Eur Urol 70:771–775. https://doi.org/10.1016/j.eururo.2016.04.037CrossRefPubMedPubMedCentral

Title: Survival of contemporary patients with non-metastatic urachal vs. non-urachal adenocarcinoma of the urinary bladder
Authors: Stefano Luzzago
Carlotta Palumbo
Giuseppe Rosiello
Angela Pecoraro
Marina Deuker
Francesco Alessandro Mistretta
Zhe Tian
Gennaro Musi
Emanuele Montanari
Shahrokh F. Shariat
Fred Saad
Alberto Briganti
Ottavio de Cobelli
Pierre I. Karakiewicz
Publication date: 01-11-2020
Publisher: Springer Berlin Heidelberg
Keyword: Cystectomy
Published in: World Journal of Urology / Issue 11/2020
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-020-03083-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Survival of contemporary patients with non-metastatic urachal vs. non-urachal adenocarcinoma of the urinary bladder

Abstract

Purpose

Materials and methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 11/2020

The relationship between glucose homeostasis status and prostate size in aging Chinese males with benign prostatic hyperplasia

Five compelling UTI questions after kidney transplant

A treatment strategy to help select patients who may not need secondary intervention to remove symptomatic ureteral stones after previous stenting

Urological infections in the developing world: an increasing problem in developed countries

Leydig-cell tumour of the testis: retrospective analysis of clinical and therapeutic features in 204 cases

Candida urinary tract infections in adults